Navigation Links
Use of Rx to OTC Switch as Product Management Tactic Enjoys Comeback
Date:4/10/2008

NEW YORK, April 10 /PRNewswire/ -- There are 14 prescription drugs that exceeded $20 billion in sales in 2006, that may have the potential to reach the over-the-counter market in four years. Prescription to OTC switches were frequent in 2006 and 2007 and a new report by Kalorama Information, The Return of the Rx to OTC Switch: Market Analysis and Product Management Strategies, predicts this trend will continue.

The markets for Rx to OTC are forecast to reach $5 billion in 2008 and increase by close to 40% by 2010. More than half of the revenues in 2008 will be from allergy medications that have already made the switch, such as Claritin, Benadryl, Sudafed, Nasalcrom, Mucinex and most recently Zyrtec. However, the forecast compound annual growth rate from antilipidemic agent switches between 2008 and 2013 far outpaces that of the allergy category (127.5% versus 3%).

"Lagging FDA approvals led to a brief absence of Rx to OTC switches in the pharmaceutical marketplace, but 2006 and 2007 saw a number of switches," notes Melissa Elder, the report's author. "We believe this product management tactic will continue to be aggressively utilized as companies seek ways to extend revenue lifecycles."

Factors affecting this recent upswing in Rx to OTC switches include patent expirations, generic competition, suitability for OTC shelves, drug safety and efficacy, petitions to the FDA and manufacturer trends. Some future potential switches include leading gastrointestinal drugs Prevacid, Protonix and AcipHex; antilipidemic agents Mevacor, Pravachol, Lescol and Zocor; the allergy treatment Allegra; the migraine therapy Imitrex, and a number of oral contraceptives.

Kalorama Information's report Return of the Rx to OTC Switch: Market Analysis and Product Management Strategies contains a complete overview of the U.S. market for prescription drugs likely to switch in 14 different drug categories. Forecasts are provided for each segment for the years 2008 to 2013. The report includes current issues and trends affecting the industry and identifies trends that may arise in the future. The information and forecasts were gathered through secondary research and interviews conducted with industry executives. The report can be purchased directly from Kalorama Information by visiting http://www.kaloramainformation.com/Return-Rx-OTC-1692599/.

About Kalorama Information

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. Kalorama routinely assists media with healthcare topics, and can provide experts to speak about markets in the life sciences industry. For more information, contact Andrea Hiller at 212-807-2673 or press@kaloramainformation.com, or visit http://www.kaloramaInformation.com.


'/>"/>
SOURCE Kalorama Information
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Nanoswitches toggled by light
2. New FTMS System From Varian, Inc. Offers Switchable LC and GC Sources and True Triple Quadrupole Capabilities
3. Ultrafast optical shutter is switched entirely by laser light
4. BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology
5. PerOs obtains USDA Establishment and Product Licenses for its oral vaccine formulations
6. U.S. Army Awards General Dynamics Contract for Biological Detection System Production and Support
7. Bluestar Silicones Introduces Three New Soft and Durable Liquid Silicone Rubber Products
8. Campbell Alliance Managed Markets Practice to Take a Leadership Role at the CBI Forum on Effective Product Pricing and Modeling Strategies
9. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
10. Excipients Help Pharma Extend Product Life, Profits
11. ActivBiotics Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017 Research and Markets has ... report to their offering. ... The Global Market for Bioproducts ... 2016 at a CAGR of 8.9%, This ... bioproducts into seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals ...
(Date:3/23/2017)...  GlobeImmune, Inc. today announced it has entered into ... shares of its common stock to NantCell, Inc., a ... the sale of its common stock, NantCell has agreed ... GlobeImmune 200,000 shares, an estimated $2.0 million in value, ... pleased to enter into this strategic agreement with NantCell," ...
(Date:3/23/2017)... , March 23, 2017 Kineta, ... development of novel therapies in immuno-oncology, today announced ... lead" small molecule compounds that activate interferon response ... pathways and demonstrate immune-mediated tumor regression in a ... the study who demonstrated complete tumor regression to ...
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company Cool ... financing and note conversion to commercialize its Cool Terra ... focused on developing products that are simultaneously profitable as ... in the last 18 months. This latest round of ... Venture Partners. The company,s primary product, ...
Breaking Biology Technology:
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by ... Global Forecast to 2022", published by MarketsandMarkets, the market is expected to be ... 2017 and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... Vigilant Solutions , a vehicle location ... announced today the appointment of retired FBI special agent ... business development. Mr. Sheridan brings more than ... focus on the aviation transportation sector, to his new ... Sheridan served as the Aviation Liaison Agent Coordinator (ALAC) ...
(Date:3/13/2017)... HAMBURG, Germany , March 13, 2017 Future of ... ... DERMALOGs Face Matching enables to match ... characteristics forms the basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for ...
Breaking Biology News(10 mins):